Mira Pharmaceuticals Unveils Promising Results for SKNY-1, Showing 30% Weight Loss and Reduced Cravings in Obesity Study
Mira Pharmaceuticals Inc. $(MIRA)$ has announced new results from an animal study involving SKNY-1, an oral therapeutic under definitive agreement for acquisition from SKNY Pharmaceuticals, Inc. The study, conducted using a zebrafish model that simulates human obesity and craving behaviors, demonstrated that SKNY-1 achieved significant outcomes within six days of treatment. Notably, SKNY-1 resulted in up to 30% weight loss while preserving muscle density, increased metabolic activity, and improved liver and lipid profiles. Additionally, SKNY-1 was found to reduce nicotine cravings and compulsive behaviors, as well as normalize neurohormonal imbalances associated with obesity. These findings support the advancement of SKNY-1 toward Investigational New Drug $(IND.AU)$-enabling studies, with Mira Pharmaceuticals prioritizing it as a potential cornerstone asset in light of the significant global market opportunity for obesity and smoking-related therapies.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-017046), on June 30, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.